Non-small cell lung cancer (NSCLC) is a common and rapidly fatal cancer for which targeted therapies have been markedly effective in about 20% of patients, specifically those with EGFR mutations, ROS1 rearrangements, or EML4-ALK translocations. This evidence concerns the gene EGFR and cancer.